Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer releases rivaroxaban trial results

Bayer releases rivaroxaban trial results

25th June 2008

Results from a recent rivaroxaban trial have been released.

The trial found hip replacement patients who were given one tablet daily over a five-week period of the anticoagulant drug rivaroxaban had significantly fewer venous blood clots than those given a two-week course of enoxaparin followed by a placebo.

Bayer Healthcare and Johnson & Johnson are jointly developing rivaroxaban.

Results from the trial demonstrate the safeness of rivaroxaban in comparison to enoxaparin, according to Bayer.

Patients on the rivaroxaban course had a 79 per cent relative risk reduction (RRR) in total venous thromboembolic events in comparison to the enoxaparin course, the study found.

“This study is the largest to date evaluating the need for and benefits of continuing measures beyond hospital stay to prevent blood clots after major orthopaedic surgery,” said Professor Ajay K Kakkar, principal investigator of the study and director of the Thrombosis Research Institute in London.

Bayer recently announced it is to invest 100 million euros (79 million pounds) in its sites in Brazil at the end of 2009.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.